๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-08-17

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (NCT07001748)

Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II

๐ŸŸข Recruiting Phase2 / Phase3 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: ECOG-ACRIN Cancer Research Group

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitaxel chemotherapy directly into your abdominal cavity, in addition to chemotherapy given through a vein in your arm help you live longer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your gastric cancer. The usual approach is defined as care most people get for gastric cancer. If you decide to take part in this study, you will first receive a surgical procedure called a diagnostic laparoscopy. This will help the study doctors learn more about your gastric cancer. Laparoscopy is a minimally invasive surgery for which you will be placed under general anesthesia. Then the surgeon will make small incisions (5mm) on your belly through which a camera and thin instruments are introduced to evaluate the abdomen. This procedure takes about 1 hour to complete. Your study group will be assigned during the surgery. The study groups are described further in the 'What are the study groups?' section below. If you are placed into the study group 1, you will not have an intraperitoneal port (a small device which is placed under the skin and fat of your upper abdomen and a tube that is placed into the abdomen). If you are placed into the study group 2, you will have an intraperitoneal port placed. The reason is that in addition to standard chemotherapy, which is given through a vein in your arm, this port will be used to deliver the medication paclitaxel directly inside your abdomen when you are ready to start study treatment. It is important to know that you will not know your study group until after the surgery is over. This is because information that is learned during the surgery will help determine which study group you are put in. Once you have fully healed from this surgery, you will start study treatment. Depending on which study group you are assigned, you will either receive a standard chemotherapy regimen (the regimen will be chosen by you and your doctor) if you are in study group 1, or paclitaxel through a tube in your belly plus chemotherapy given through a vein in your arm if you are in study group 2. All participants will get treatment for three (3) months after which you will undergo reevaluation. If the disease is under control or responding to treatment, you may continue the assigned treatment until your disease gets worse, the side effects become too severe, or you may be offered a surgical procedure to remove the cancer if the amount of disease is low and can be completely removed as determined by a surgeon. There is a very small chance that during the laparoscopy surgical procedure, the doctor might find something called "intra-abdominal adhesions". These are areas where the stomach has healed previously and created scar tissue. If this scar tissue prevents the surgeon from being able to place a port in the correct area, you would be ineligible to receive the study treatment. If this happens, you may still receive standard of care therapy after your surgery, but you will not be able to continue on the study. If you have more questions about this, you can ask your surgeon or the study team to help. After you finish your study treatment, your doctor or study team will watch you for side effects. They will continue to follow your condition every three (3) months during the first two (2) years, then every six (6) months until year 5. You may be reevaluated with Chest/Abdomen/Pelvis scans every three-six (3-6) months for up to five (5) years if decided by your doctor.

Who can join: Review the eligibility criteria below.

Location: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care โ€” Irvine, California

Age range: 18 Years

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (78 Sites)

Showing the first 25 of 78 sites.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care โ€” Irvine, California
  • Cedars-Sinai Medical Center โ€” Los Angeles, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center โ€” Orange, California
  • Stanford Cancer Institute Palo Alto โ€” Palo Alto, California
  • UCHealth University of Colorado Hospital โ€” Aurora, Colorado
  • Smilow Cancer Hospital-Derby Care Center โ€” Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield โ€” Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich โ€” Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford โ€” Guilford, Connecticut
  • Yale University โ€” New Haven, Connecticut
  • Yale-New Haven Hospital North Haven Medical Center โ€” North Haven, Connecticut
  • Smilow Cancer Hospital Care Center at Long Ridge โ€” Stamford, Connecticut
  • Smilow Cancer Hospital-Torrington Care Center โ€” Torrington, Connecticut
  • Smilow Cancer Hospital Care Center-Trumbull โ€” Trumbull, Connecticut
  • Smilow Cancer Hospital-Waterbury Care Center โ€” Waterbury, Connecticut
  • Smilow Cancer Hospital Care Center - Waterford โ€” Waterford, Connecticut
  • UF Health Cancer Institute - Gainesville โ€” Gainesville, Florida
  • Emory University Hospital Midtown โ€” Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute โ€” Atlanta, Georgia
  • Emory Saint Joseph's Hospital โ€” Atlanta, Georgia
  • Northwestern University โ€” Chicago, Illinois
  • University of Chicago Comprehensive Cancer Center โ€” Chicago, Illinois
  • Northwestern Medicine Cancer Center Old Irving Park โ€” Chicago, Illinois
  • Northwestern Medicine Cancer Center Kishwaukee โ€” DeKalb, Illinois
  • Northwestern Medicine Cancer Center Delnor โ€” Geneva, Illinois

๐Ÿ“ž Contact the Study Coordinator

Phone: (877) 827-8839

Email: ucstudy@uci.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—